Projects per year
Personal profile
Education
-
2013-2019 Ph.D, School of Pharmacy, Taipei Medical University, Taipei, Taiwan
-
2004-2006 M.S. in Clinical Pharmacy, National Cheng Kung University, Tainan, Taiwan
-
2000-2004 B.S. in Pharmacy, National Taiwan University, Taipei, Taiwan
Experience
- 2025- Associate professor, School of Pharmacy, Taipei, Medical University, Taipei, Taiwan
- 2023-2025 Assistant professor, School of Pharmacy, Taipei, Medical University, Taipei, Taiwan
- 2020-2023 Adjunct assistant professor, School of Pharmacy, Taipei, Medical University, Taipei, Taiwan
- 2019 Oncology training in National Cancer Centre Singapore
- 2017- Oncology pharmacist, Wanfang Hospital
- 2016- Board Certified Oncology Pharmacist, USA
- 2015 Oncology training in University of Illinois at Chicago, USA
- 2013-2020 Adjunct instructor, School of Pharmacy, Taipei, Medical University, Taipei, Taiwan
- 2008- Pharmacist, Department of Pharmacy, Wanfang Hospital
Research Interests
-
Clinical pharmacy
-
Cancer pharmacotherapy
-
Pharmacogenomic
Fingerprint
Dive into the research topics where Chun-Nan Kuo is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 3 Finished
-
Impacts of the Response to Immune Checkpoint Inhibitors in Cancer Therapy: from Clinical Use to Gene Analysis
Kuo, C.-N. (PI)
8/1/24 → 7/31/25
Project: A - Government Institution › b - National Science and Technology Council
-
新聘教師研究補助
Kuo, C.-N. (PI)
1/15/24 → 1/14/25
Project: B - Project of TMU › g - Research Grants for Newly Hired Faculty
-
Using Genomic Database to Explore the Treatment Target of Pancreatic Cancer and Possible Drugs
Kuo, C.-N. (PI)
8/1/20 → 12/31/21
Project: A - Government Institution › b - National Science and Technology Council
-
Cumulative Dose of Regorafenib in Patients With Metastatic Colorectal Cancer: A Multicenter Cohort Study
Kuo, Y. H., Kuo, C. N., Chang, C. L. & Ko, Y., Jul 2025, In: Journal of Gastroenterology and Hepatology (Australia). 40, 7, p. 1745-1753 9 p.Research output: Contribution to journal › Article › peer-review
1 Citation (Scopus) -
Effectiveness and Safety of Reduced and Standard Initial Doses of Regorafenib in Patients With Metastatic Colorectal Cancer: A Multicenter Retrospective Study in Taiwan
Kuo, Y. H., Kuo, C. N., Chang, C. L. & Ko, Y., Nov 2025, In: Pharmacoepidemiology and Drug Safety. 34, 11, e70221.Research output: Contribution to journal › Article › peer-review
-
Effectiveness and Safety of Regorafenib and TAS-102 in Patients with Metastatic Colorectal Cancer: A Nationwide Population-Based Study in Taiwan
Chang, Y. W., Kuo, C. N., Chang, C. L., Hsu, J. C. & Ko, Y., Jul 2025, In: Cancer Research and Treatment. 57, 3, p. 830-839 10 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Evaluating the cost-effectiveness of atezolizumab-bevacizumab in advanced hepatocellular carcinoma: Insights from Taiwan
Chang, T. W., Chang, W. C., Chou, W. H., Chang, W. P. & Kuo, C. N., 2025, In: Journal of Food and Drug Analysis. 33, 2, p. 163-171 9 p.Research output: Contribution to journal › Article › peer-review
-
Sequential Treatment of Metastatic Colorectal Cancer in Taiwan: Real-World Evidence From Regorafenib and Trifluridine/Tipiracil Use
Chang, Y. W., Kuo, C. N., Chang, C. L., Hsu, J. & Ko, Y., 2025, (Accepted/In press) In: Journal of Gastroenterology and Hepatology (Australia). 40, 5, p. 1135-1142 8 p.Research output: Contribution to journal › Article › peer-review